A WISH LIST FOR DISRUPTIVE INNOVATORS

OxSTEM
A WORLD CLASS REGENERATIVE MEDICINE DRUG DISCOVERY COMPANY

NOVEMBER 2017
OxStem Mission

Our Purpose and What We Do

To help people with latent and degenerative diseases or injuries live healthier, longer lives

✓ OxStem develops small molecules for stimulation of stem and progenitor cells in situ

✓ OxStem’s approach to regenerative medicine will deliver small molecule therapeutics that augment repair mechanisms that already exist within the body

✓ Affordable small molecule approach
**OxStem – Innovative Structure**

"OxStem 4D"
3D Stem Cell Suspension Culture

"Spin in / out"

OxStem

Accelerate

**OxStem Oncology**
Est. May 2016

**OxStem Neuro**
Est. Aug 2016

Execute

**OxStem Ocular**
Est. Aug 2016

**OxStem Cardio**
Est. Nov 2016

Establish & Drive

**OxStem Immuno**
“Immuno”

**OxStem Beta**
“Beta”
CAPITAL EFFICIENT BUSINESS MODEL

• Distributed R&D model with early discovery phase being undertaken in partnership with the University of Oxford

• OxStem works closely with world-leading scientific talent of selected Science & Medicine Departments at the University of Oxford
Wish list for disruptive innovators

- Government is traditionally bad at picking winners; but can select Regenerative Medicine within Advanced Therapies and then really back it (Japanese model). Go large or go home!

- Matched funding specific to regenerative medicine. No one likes to see money wasted, least of all the private sector. Allocate an innovation fund for the potential disruptors. (Finnish Model)

- Designation of the University of Oxford (the largest life sciences campus in Europe) as a centre for Regenerative Medicine; much greater backing for the required infrastructure. In partnership with innovators and established industry.

- Convening power (using Parliament / House of Lords / Oxford Colleges / Other) for meetings bringing international investors including industry together with start-ups in regenerative medicine. Specific Regenerative Medicine Fund for supporting meetings e.g. funding through the Oxford Institute for Stem Cell Research

- Innovate model should include ideas outside the “traditional box” i.e. outside of the the norm in regenerative medicine; this is were the disruptors will emerge from

- To reiterate: go large or go home!
“To help people with latent and degenerative diseases or injuries live healthier, longer lives”

THANK YOU!

DR. MICHAEL STEIN, CHAIRMAN AND CEO
info@oxstem.co.uk